NEXT GENERATION NANOPARTICLE-BASED ANTIBACTERIAL TREATMENT FOR INFECTED WOUNDS
Every 5th person with diabetes develops chronic wounds that are frequently infected by bacteria. In 15−27 % cases bacterial wound infection leads to the gangrene that requires an amputation of the leg. 10 mln of amputations occur...
ver más
Descripción del proyecto
Every 5th person with diabetes develops chronic wounds that are frequently infected by bacteria. In 15−27 % cases bacterial wound infection leads to the gangrene that requires an amputation of the leg. 10 mln of amputations occur annually, showing that existing wound infection management treatments are inefficient.
NEXTNANO aims to commercialize a new antibacterial nanotechology developed by our scientists and medical doctors to reduce the number of infection-related amputations by 20%. We showed in animals studies that our first product produced on the basis of this technology, an antibacterial wound dressing, is 8x times better than the current commercial best.
Women TechEU grant would support the transition of our technology from the research and development stage to the commercialization stage. For that we have 4 Objectives: 1) To upgrade the commercialization strategy of our company; 2) To conduct the clinical assessment of our first product, antibacterial wound dressing; 3) To establish the quality management system (QMS) in our company and 4) To train participants. The main project results will be the improved commercialization strategy (including new contacts with the stakeholders), collaboration with the EU key opinion leaders and established QMS that will greatly increase the connectivity and competitiveness of our women-led deep-tech startup within innovation ecosystems of the EU. This will lead to more inclusive and gender equal innovation ecosystem in EU, since Estonia is one of the EU inclusiveness target countries and has one of the EU's highest inequalities between the salaries and top positions of women and men according to Eurostat. Not least, NEXTNANO will result in significant impacts: environmental (decreased use of antibiotics), societal (20% less amputations) and economical (10 mln eur revenue by 2026 and new high value-added jobs for 15 persons such as scientists, medical doctors, engineers and sales managers).
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.